MNKD - MannKind Corporation
| Previous Close | 1.3900 |
| Open | 1.4100 |
| Bid | 1.42 x 36900 |
| Ask | 1.45 x 27000 |
| Day's Range | 1.3900 - 1.4500 |
| 52 Week Range | 0.9400 - 3.3700 |
| Volume | 1,670,251 |
| Avg. Volume | 2,253,180 |
| Market Cap | 270.083M |
| Beta (3Y Monthly) | 2.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.83 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- GuruFocus.com•12 days ago
Weekly CFO Buys Highlight
Insiders pile on shares of Dynex Capital, MannKind and Martin Midstream Partners
- GlobeNewswire•13 days ago
Market Trends Toward New Normal in MannKind, IDEX, Belden, Bright Horizons Family Solutions, Masonite International, and Veritiv — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Feb. 05, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks Small Cap Research•27 days ago
MNKD: Update From Our Meeting With MNKD at JPM
The International Diabetes Federation’s (IDF) Diabetes Atlas (8th edition) has estimated that approximately 30 million people were living with diabetes in 2017 in the U.S. According to the CDC, about 1.5 million new cases are diagnosed per year. Although insulin injection pens are ubiquitous and generally convenient to carry around, adherence to therapy has remained a challenge primarily due to hypo/hyperglycemia and, to some extent, as a result of anxiety associated with an injection, local sensitivity, pain and bruising. One of the biggest challenges for the company has been accelerating growth of Afrezza.
- ACCESSWIRE•27 days ago
Biotech Stocks on the Move
HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotech has been one of the hottest sectors this month. Investors are intrigued by the increase in M&A. Now's a great time to start researching some oversold ...
- MarketWatch•last month
How to spot risky biotech companies and six to avoid now
With biotechnology exchange traded funds down as much as 20% from their highs last year, it’s now tempting to shop for bargains. It had cash of $11 million and annualized losses of $94 million, for a very troubling risk ratio of 0.1.
- GlobeNewswire•last month
MannKind Announces Direct Purchase Insulin Program Providing Afrezza® for as low as $4 a Day
MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced a direct purchase program to help those with diabetes obtain the company’s inhaled insulin, Afrezza, for as little as $4 a day.
- GlobeNewswire•2 months ago
MannKind Corporation to Hold Investor Conference Call
WESTLAKE VILLAGE, Calif., Dec. 27, 2018 -- MannKind Corporation (NASDAQ: MNKD) will host a conference call on Friday, January 4, 2019 to discuss Company developments at 9:00 AM.
- Simply Wall St.•2 months ago
How Many MannKind Corporation (NASDAQ:MNKD) Shares Do Institutions Own?
A look at the shareholders of MannKind Corporation (NASDAQ:MNKD) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to Read More...
- Motley Fool•2 months ago
Why MannKind Stock Is Plunging Today
Shares tumble after the biopharma raises capital from a dilutive common-stock offering.
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and MannKind
NEW YORK, NY / ACCESSWIRE / December 20, 2018 / U.S. equities closed down on Wednesday as the anticipated interest rate increase was confirmed by the Federal Reserve, following Chairman Jerome Powell’s ...
- GlobeNewswire•2 months ago
MannKind Announces Pricing of $40 Million Public Offering
MannKind Corporation (MNKD) (MannKind) today announced the pricing of an underwritten public offering of 26,666,667 shares of its common stock and warrants to purchase up to an aggregate of 26,666,667 shares of its common stock. Each share of common stock is being sold together with a warrant to purchase one share of common stock for a combined purchase price of $1.50, for a gross deal size of $40.0 million, not including any future proceeds from the exercise of the warrants and before deducting the underwriting discounts and commissions and offering expenses. The shares of common stock and warrants can only be purchased together but will be issued separately and will be immediately separable upon issuance. The offering is expected to close on December 26, 2018, subject to customary closing conditions.
- GlobeNewswire•2 months ago
MannKind Announces Commencement of Public Offering
MannKind Corporation (MNKD) (MannKind) today announced that it has commenced an underwritten public offering to issue and sell shares of its common stock and warrants to purchase shares of its common stock. Leerink Partners is acting as sole book-running manager for the offering. The securities described above are being offered by MannKind pursuant to a shelf registration statement on Form S-3 (No. 333-210792) previously filed by MannKind with the Securities and Exchange Commission (SEC) on April 18, 2016 and declared effective on April 27, 2016.
- Zacks Small Cap Research•2 months ago
MNKD: Zacks SCR Initiates Coverage of MannKind With $4.25/share Price Target
Zacks SCR analysts Brian Marckx, CFA and Anita Dushyanth, PhD have initiated coverage of MannKind Corporation with a $4.25/share price target. MannKind Corporation (MNKD) was founded in the early 2000’s by the late Alfred Mann, a physicist by training, Mann was a pioneer in several fields including aerospace, electronics and medical devices. Among his successes prior to MannKind was development of the first rechargeable pacemaker and MiniMed, a revolutionary miniaturized insulin pump that was sold to Medtronic in 2001 for more than $3B.
- ACCESSWIRE•2 months ago
Biotech Stocks Beating the Market
HENDERSON, NV / ACCESSWIRE / December 10, 2018 / Here are several biotech plays to pay close attention to in the coming sessions. Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), MannKind ...
- GlobeNewswire•3 months ago
MannKind Appoints Christine Mundkur to its Board of Directors
MannKind Corporation (MNKD) today announced that Christine Mundkur has joined its Board of Directors, effective November 27, 2018. Ms. Mundkur will also serve as a member of the Audit Committee of the Board. Ms. Mundkur brings 25 years of experience in the pharmaceutical industry to the MannKind Board. “Christine brings a tremendous wealth of experience to our board of directors,” said Kent Kresa, Chairman of the Board of MannKind Corporation.
- American City Business Journals•3 months ago
Analysts: Why United Therapeutics has had a streak of licensing deals
United Therapeutics Corp. has been striking more licensing deals this year, a trend some analysts say illustrates the company’s strategy to staying ahead of generic competition. The Silver Spring drugmaker announced a global licensing agreement earlier this month with California company Arena Pharmaceuticals Inc. (NASDAQ: ARNA). United Therapeutics (NASDAQ: UTHR) will pay Arena $800 million upfront, plus up to $400 million in milestone payments, for exclusive rights to ralinepag, a phase 3 investigational drug candidate in development for pulmonary arterial hypertension.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of MNKD earnings conference call or presentation 1-Nov-18 1:00pm GMT
Q3 2018 MannKind Corp Earnings Call
- Associated Press•4 months ago
MannKind: 3Q Earnings Snapshot
On a per-share basis, the Westlake Village, California-based company said it had a loss of 16 cents. The biopharmaceutical company posted revenue of $4.5 million in the period. The company's shares closed ...
Motley Fool•4 months agoUnited Therapeutics Corp (UTHR) Q3 2018 Earnings Conference Call Transcript
UTHR earnings call for the period ending September 30, 2018.
- ACCESSWIRE•4 months ago
Today’s Research Reports on Stocks to Watch: Altimmune and MannKind
NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Altimmune and MannKind were two biotech stocks flying higher in Tuesday’s session. Altimmune didn’t have any particular news but MannKind announced along ...
- Motley Fool•4 months ago
Why MannKind Corp. Soared 16.4% Tuesday
The company has completed its planned transaction with United Therapeutics.
- PR Newswire•4 months ago
United Therapeutics And MannKind Announce Closing Of License And Collaboration Agreement
RESEARCH TRIANGLE PARK, N.C. and WESTLAKE VILLAGE, Calif., Oct. 16, 2018 /PRNewswire/ -- United Therapeutics Corporation (UTHR) and MannKind Corporation (MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.
